Cargando…

Risk of bradycardia with lopinavir/ritonavir in COVID-19 patients

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7378989/ http://dx.doi.org/10.1007/s40278-020-80996-7

Ejemplares similares

Lopinavir/ritonavir delays COVID-19 recovery in paediatric patients
Publicado: (2022)

Hydroxychloroquine/lopinavir/ritonavir: Bradycardia and off-label-use: case report
Publicado: (2021)

Crushing lopinavir/ritonavir tablets does not result in lower exposure to lopinavir/ritonavir in adult patients with COVID-19
por: Mohsenian Naghani, Shaghayegh, et al.
Publicado: (2023)

Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients
por: Alvarez, Jean Claude, et al.
Publicado: (2020)

Remdesivir versus ritonavir/lopinavir in COVID-19 patients
por: Vitiello, Antonio, et al.
Publicado: (2020)

Maculopapular rash in COVID-19 patient treated with lopinavir/ritonavir
por: Mazan, Paula, et al.
Publicado: (2020)

Brief Report: Retrospective Evaluation on the Efficacy of Lopinavir/Ritonavir and Chloroquine to Treat Nonsevere COVID-19 Patients
por: Gao, Guiju, et al.
Publicado: (2020)

Serotonin syndrome in two COVID-19 patients treated with lopinavir/ritonavir
por: Mas Serrano, Miguel, et al.
Publicado: (2020)

Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19
por: Zhu, Zhen, et al.
Publicado: (2020)

Lopinavir-Ritonavir-Kombination nicht wirksam
por: Diener, Hans-Christoph
Publicado: (2020)

Lopinavir/ritonavir monotherapy in clinical practice
por: Caso, A, et al.
Publicado: (2010)

An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19
por: Ader, Florence, et al.
Publicado: (2021)

Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial
por: Li, Yueping, et al.
Publicado: (2020)

Data on compounding lopinavir and ritonavir suspension for non-cooperative COVID-19 patients
por: Zanon, D., et al.
Publicado: (2020)

Potential drug–drug interactions in COVID 19 patients in treatment with lopinavir/ritonavir()
por: Brandariz-Nuñez, David, et al.
Publicado: (2020)

Once vs. twice-daily lopinavir/ritonavir in HIV-1-infected children
Publicado: (2015)

Lopinavir-Ritonavir in the Treatment of COVID-19: A Dynamic Systematic Benefit-Risk Assessment
por: Osborne, Vicki, et al.
Publicado: (2020)

A severe COVID-19 despite ongoing treatment with Lopinavir-Ritonavir
por: Joumaa, H., et al.
Publicado: (2020)

A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
por: Cao, Bin, et al.
Publicado: (2020)

Lopinavir/ritonavir use in Covid-19 infection: is it completely non-beneficial?
por: Owa, Adewale Bayode, et al.
Publicado: (2020)

Brief Report: Suboptimal Lopinavir Exposure in Infants on Rifampicin Treatment Receiving Double-dosed or Semisuperboosted Lopinavir/Ritonavir: Time for a Change
por: Jacobs, Tom G., et al.
Publicado: (2023)

Propofol/lopinavir/ritonavir: Bradyarrythmia: case report
Publicado: (2020)

An open-label randomized, controlled trial of the effect of lopinavir and ritonavir, lopinavir and ritonavir plus interferon-β-1a, and hydroxychloroquine in hospitalized patients with COVID-19: final results
por: Ader, Florence
Publicado: (2022)

Acute Kidney Injury Associated With Lopinavir/Ritonavir Combined Therapy in Patients With COVID-19
por: Binois, Yannick, et al.
Publicado: (2020)

Crushing lopinavir-ritonavir tablets may decrease the efficacy of therapy in COVID-19 patients
por: Eljaaly, Khalid, et al.
Publicado: (2020)

Effect of hydroxychloroquine, azithromycin and lopinavir/ritonavir on the QT corrected interval in patients with COVID-19
por: Echarte-Morales, Julio, et al.
Publicado: (2021)

Therapy with lopinavir/ritonavir and hydroxychloroquine is associated with acute kidney injury in COVID-19 patients
por: Schneider, Johanna, et al.
Publicado: (2021)

Three Novel COVID-19 Pneumonia Cases Successfully Treated With Lopinavir/Ritonavir
por: Wada, Tatsuhiko, et al.
Publicado: (2020)

Early administration of ritonavir-boosted lopinavir could prevent severe COVID-19
por: Klement-Frutos, Elise, et al.
Publicado: (2021)

Lopinavir/ritonavir: Repurposing an old drug for HIV infection in COVID-19 treatment
por: Magro, Paola, et al.
Publicado: (2021)

Possible nirmatrelvir/ritonavir-induced bradycardia in a patient with asymptomatic COVID-19
por: DeMarco, Elizabeth, et al.
Publicado: (2023)

Hypertriglyceridaemia and the risk of pancreatitis six months post lopinavir/ritonavir initiation
por: Greffrath, Wilhelm P., et al.
Publicado: (2018)

Lopinavir/ritonavir: vomiting and watery diarrhoea: case report
Publicado: (2020)

Modulations of human placental transfer of lopinavir, ritonavir and enfuvirtide
por: Ceccaldi, Pierre-François, et al.
Publicado: (2010)

The administration of lopinavir/ritonavir via an enteral feeding tube()
por: Sirvent Segovia, Alejandro Esteban, et al.
Publicado: (2021)

Prediction of lopinavir/ritonavir effectiveness in COVID-19 patients: a recall of basic pharmacology concepts
por: Cattaneo, Dario, et al.
Publicado: (2020)

Potentially fatal severe brady arrythmias related to Lopinavir-Ritonavir in a COVID 19 patient
por: Shree, Venkatesan, et al.
Publicado: (2021)

Lopinavir/ritonavir for treatment of non-hospitalized patients with COVID-19: a randomized clinical trial
por: Kaizer, Alexander M., et al.
Publicado: (2023)

High rate of major drug–drug interactions of lopinavir–ritonavir for COVID-19 treatment
por: Macías, Juan, et al.
Publicado: (2020)

Effectiveness of Remdesivir, Lopinavir/Ritonavir, and Favipiravir for COVID-19 Treatment: A Systematic Review
por: Qomara, Windi Fresha, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_27be7geeffb6itjq2r2tjlbvc8